Last reviewed · How we verify
NCT02539329
Characterization of Anti-FGFR3 Antibodies
trial testing Neurological assessment and Blood sample in Sensory Peripheral Neuropathy in 251 participants. Completed in 17 January 2022.
15 November 2021
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Saint Etienne |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 251 |
| Start date | 3 February 2015 |
| Primary completion | 15 November 2021 |
| Estimated completion | 17 January 2022 |
| Sites | 17 locations across France |
Drugs / interventions tested
- Neurological assessment and Blood sample
Conditions studied
- Sensory Peripheral Neuropathy — all drugs for Sensory Peripheral Neuropathy →
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Who can join
18 and older, any sex, with Sensory Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sensory neuronopathies affect sensory neuron in the posterior spinal ganglion. They are responsible for pain, balance disorder (ataxia) and the use of hands. They depend on multiple etiologies. In a retrospective study, the investigators showed that the anti-FGFR3 antibody is a diagnostic marker of a subset of sensory neuronopathies. The investigators believe that other antibodies can be discovered in patients who remain seronegative changing. However, the study is retrospective and only a small number of patients could be identified. Several points therefore need to be clarified or confirmed in a second prospective study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02539329
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire de Saint Etienne trials
Trials by the same sponsor.
- NCT07326579 — Effects of a Sleep Education Program on the Health Status of Healthcare Workers Working 12-hour Alternating Day-night Sh · NA · not yet recruiting
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07483710 — Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission an · NA · not yet recruiting
- NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
- NCT07344298 — Less is Better? Effectiveness of a Short Local Vibration Protocol on Neuromuscular Function · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02539329 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Saint Etienne
- Last refreshed: 10 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02539329.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing